4/25
07:00 am
btai
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
Medium
Report
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
4/24
10:49 am
btai
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting [Y
Low
Report
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting [Y
4/24
10:30 am
btai
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
Medium
Report
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
4/23
08:09 am
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
4/22
07:00 am
btai
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
Medium
Report
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
4/10
07:17 am
btai
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia [Yahoo! Finance]
Low
Report
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia [Yahoo! Finance]
4/10
07:00 am
btai
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
Low
Report
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
3/25
09:02 am
btai
BioXcel launches $25M direct offering of stock and warrants [Seeking Alpha]
High
Report
BioXcel launches $25M direct offering of stock and warrants [Seeking Alpha]
3/25
08:45 am
btai
Borr Drilling, Aehr Test Systems, Airship AI among premarket losers' pack [Seeking Alpha]
High
Report
Borr Drilling, Aehr Test Systems, Airship AI among premarket losers' pack [Seeking Alpha]
3/25
07:05 am
btai
BioXcel Therapeutics Announces $25 Million Registered Direct Offering [Yahoo! Finance]
Medium
Report
BioXcel Therapeutics Announces $25 Million Registered Direct Offering [Yahoo! Finance]
3/25
07:00 am
btai
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
High
Report
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
3/24
08:35 am
btai
BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint [Yahoo! Finance]
Low
Report
BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint [Yahoo! Finance]
3/18
03:14 pm
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its price target lowered by analysts at Bank of America Co. from $8.00 to $7.00. They now have a "buy" rating on the stock.
Low
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its price target lowered by analysts at Bank of America Co. from $8.00 to $7.00. They now have a "buy" rating on the stock.
3/18
03:09 pm
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $18.00 to $7.00. They now have a "buy" rating on the stock.
Low
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $18.00 to $7.00. They now have a "buy" rating on the stock.
3/18
02:52 pm
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
3/15
07:16 am
btai
BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine [Yahoo! Finance]
Medium
Report
BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine [Yahoo! Finance]
3/15
07:00 am
btai
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
High
Report
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
3/13
09:22 am
btai
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/12
07:17 am
btai
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 [Yahoo! Finance]
High
Report
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 [Yahoo! Finance]
3/12
07:00 am
btai
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
Medium
Report
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
3/1
07:00 am
btai
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
Low
Report
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
2/21
08:00 am
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $4.00 price target on the stock, down previously from $9.00.
Medium
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $4.00 price target on the stock, down previously from $9.00.
2/13
09:16 am
btai
BioXcel Therapeutics Announces Termination of Proposed Public Offering [Yahoo! Finance]
Medium
Report
BioXcel Therapeutics Announces Termination of Proposed Public Offering [Yahoo! Finance]
2/13
09:00 am
btai
BioXcel Therapeutics Announces Termination of Proposed Public Offering
High
Report
BioXcel Therapeutics Announces Termination of Proposed Public Offering
2/12
07:22 am
btai
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) [Yahoo! Finance]
High
Report
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) [Yahoo! Finance]